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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/$36 Copyright ª 2013, TaiwGabapentin is well known for its pain control and antiepileptic effect, but its antiemetic effect
is poorly investigated. Here we report on effective gabapentin use for refractory vomiting after
craniotomy in two children with medulloblastoma in the fourth ventricle. The two pediatric
patients (an 11-year-old girl and a 4-year-old boy) underwent near-total excision of the tumor
via craniotomy. Both patients suffered from refractory postoperative nausea and vomiting,
treated with multiple traditional antiemetic drugs but without relief. After gabapentin intake,
their nausea and vomiting improved from one to two episodes per day to complete resolution
of symptoms. This report suggests that gabapentin may be a novel antiemetic therapeutic
intervention for patients with refractory nausea and vomiting after craniotomy.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Postoperative nausea and vomiting are frequently observed
in patients who have undergone craniotomy.1 A midlineNeurology, Department of
Hospital, Number 8, Chung-
w (P.-C. Fan).
013.04.002
an Pediatric Association. Publishlocation of tumor is considered a risk factor for post-
operative vomiting in children requiring posterior fossa
tumor resection and may be refractory to current anti-
emetic agents.2
Gabapentin is a structural analogue of the neurotrans-
mitter gamma-aminobutyric acid (GABA). However, unlike
GABA, which does not cross the bloodebrain barrier,
gabapentin penetrates into the central nervous system, and
its activity is distinct from GABA-related effects.3 It is an
anticonvulsant that has been approved by the US Food anded by Elsevier Taiwan LLC. All rights reserved.
352 K.-C. Tsai et alDrug Administration since 1994 as adjunct therapy for
partial seizures and postherpetic neuralgia. Gabapentin is
also known for reducing hot flashes in menopausal women
and in women with breast cancer,4 while its antiemetic
effect has been documented in chemotherapy-induced
nausea in breast cancer patients,5 postoperative nausea
and vomiting in patients undergoing laparoscopic chole-
cystectomy,6 and in hyperemesis gravidarum.7
The use of gabapentin for treating post-craniotomy
vomiting in pediatric patients with posterior fossa tumor
has not been reported in the literature to date. Herein is a
report of the satisfactory antiemetic effect of gabapentin
in two children with medulloblastoma who suffered from
refractory nausea and vomiting after craniotomy for tumor
excision.
2. Case Report
2.1. Case 1
An 11-year-old girl consulted for vomiting once or twice per
week for two months with associated dizziness and head-
ache. Neurological examination revealed significantFigure 1 Pre- and postoperative brain magnetic resonance imag
globular mass lesion measuring 4.3 cm  4.4 cm  3.8 cm in dia
Medulloblastoma has been documented by pathology. (C and D) Th
and resolution of hydrocephalus.dysmetria and clumsy tandem gait. Brain magnetic reso-
nance imaging (MRI) revealed a globular mass lesion
measuring 4.3 cm  4.4 cm  3.8 cm in diameter in the
fourth ventricle with obstructive hydrocephalus (Figure 1A
and B). Near-total excision of the tumor via craniotomy,
along with placement of transient external ventricular
drainage, was done in January 2009 and the pathology
report confirmed the diagnosis of medulloblastoma. The
postoperative image is shown in Figure 1C and D. The tumor
stage was T2M0 according to Chang’s system. The patient
was discharged under stable condition, and radiotherapy
(5400 rad in 30 fractions for 6 weeks) was started 1 month
after surgery. Chemotherapy was not performed in this
patient.
Bursts of vomiting about 10 times per day developed
for 3 days, and the patient was admitted for vomiting
control. Intravenous metoclopramide and granisetron
were initially prescribed, and the vomiting ceased.
However, the vomiting recurred shortly after the regimen
was shifted to oral metoclopramide. Oral domperidone
(10 mg four times a day) was added and appeared to be
partially effective. Another episode of unstoppable
vomiting occurred again 2 weeks later, about nine times
per day, which required readmission. Intravenousing of Case 1. (A and B) The preoperative brain scan shows a
meter in the fourth ventricle with obstructive hydrocephalus.
e postoperative image shows near-total excision of the tumor
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and were then replaced by oral ondansetron (8 mg three
times a day).
After discharge, intermittent vomiting of one to three
times a week persisted even after the completion of
radiotherapy. Follow-up brain MRI 3 months post-surgery
showed no evidence of tumor relapse or hydrocephalus.
Oral topiramate (25 mg twice daily) was added along with
ondansetron, but with minimal benefit. After thorough
discussion with the family, gabapentin (oral 300 mg twice
daily) was added and the patient’s vomiting ceased. Top-
iramate and ondansetron were gradually tapered without
recurrence of vomiting. After more than 1 year since the
start of gabapentin, no side effect has been reported.2.2. Case 2
A four-year-old boy presented to the neurology clinic with
ataxic gait and vomiting for 2 months. Brain MRI revealed a
5.4 cm  4.6 cm  4.4 cm tumor within the fourth ventricle
extending to the left foramen of Luschka with diffusely
enlarged lateral and third ventricles resulting in obstructive
hydrocephalus (Figure 2A andB). Sub-occipital craniotomy forFigure 2 Pre- and postoperative brain magnetic resonance ima
5.4 cm  4.6 cm  4.4 cm tumor within the fourth ventricle extendi
and third ventricles resulting in obstructive hydrocephalus. (C) Me
operative image shows near-total excision of the tumor and impronear-total excision along with the placement of transient
external ventricular drainagewas performed inMay 2009. The
postoperative brain MRI scan is shown in Figure 2C. The pa-
thology report confirmed the diagnosis of medulloblastoma.
The tumor stage was T3aM0 according to Chang’s system.
Chemotherapy was started and intermittent post-
prandial vomiting occurred daily, even when chemotherapy
was not given. Increased intracranial pressure was initially
suspected but was excluded by brain computed tomography
scan and MRI. Electroencephalography revealed focal
cortical dysfunction in the right temporal and bilateral
frontal areas. Epileptic vomiting was suspected, so oxcar-
bazepine was added for 2 months but without relief of
symptoms. The regimen was shifted to topiramate 25 mg
twice daily (1.388 mg/kg/dose) but also in vain. Gabapentin
was then added at a dose of 100 mg twice daily and the
vomiting ceased. Gabapentin was gradually tapered off
8 months later without recurrence of vomiting.3. Discussion
Patients who undergo craniotomy often experience post-
operative nausea and vomiting. The estimated frequenciesging of Case 2. (A and B) The preoperative image reveals a
ng to the left foramen of Luschka with diffusely enlarged lateral
dulloblastoma has been documented by pathology. The post-
vement of hydrocephalus.
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respectively.8 According to previous reports, acute post-
craniotomy vomiting (emesis during the first 24 hours
after an operation) occurs in approximately 50% of pa-
tients, but it can be prevented by intravenous ondanse-
tron.9,10 In chronic postoperative vomiting, management is
usually frustrating, with the adverse consequences of
dehydration, electrolyte imbalance, hypochloremic meta-
bolic alkalosis, aspiration pneumonia, and failure to thrive
in the pediatric population.
Children who require posterior fossa craniotomy appear
to be at risk of nausea and vomiting. Posterior fossa takes
place below the tentorium. The reticulospinal tracts,
diencephalon, limbic system, and discrete areas of cerebral
hemispheres may all be involved in nausea, retching, and
vomiting. Also, the coordination of autonomic changes
associated with retching and vomiting occurs at the level of
the medulla oblongata in the posterior fossa. Thus, from an
anatomical perspective, surgeries that are proximal to this
area may place patients at high risk of vomiting.
There is some evidence that tachykinin activity is part of
the pathogenesis of chemotherapy-induced emesis in fer-
rets,11 and a selective tachykinin receptor antagonist
improved both acute (within 24 hours) and delayed (on days
2e5) chemotherapy-induced nausea and vomiting in
humans.12 It is suggested that mitigating tachykinin
neurotransmitter activity is implicated in Gabapentin’s
mechanism of action in the treatment of hot flashes.5
The antiemetic effect of gabapentin has been reported
in chemotherapy in patients with breast cancer, hyper-
emesis gravidarum, and the prevention of postoperative
vomiting.6 There is a case report on the satisfactory effect
of gabapentin-scopolamine therapy in an adult patient who
underwent posterior fossa cholesteatoma resection and
subsequently suffered from severe refractory chronic
emesis.13 From our report, gabapentin may be used in
treating post-craniotomy vomiting in pediatric patients
with posterior fossa tumor.
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